Between the Lines: Interpreting Emerging Clinical Trial Data for Talquetamab in Relapsed/Refractory Multiple Myeloma Clinical Perspectives on MonumenTAL-3 and Emerging Bispecific Antibody Strategies

Experts unpack how frontline CD38 quadruplets reshape relapse strategy and high‑risk definitions, spotlighting talquetamab’s promise in myeloma.

New trials show BCMA bispecifics and CAR‑T boost survival in early relapsed, high‑risk myeloma, outperforming Dara-based triplets.